HOME >> MEDICINE >> NEWS
Researchers identify less expensive HIV progression test as effective as current tests in use

Researchers at the Johns Hopkins University Bloomberg School of Public Health and the University of Zurich, Switzerland, have identified a test for monitoring the progression of HIV in the early stages of the disease, which is less expensive than current tests used to monitor the progression of HIV. The test, called HIV-1 protein 24 (p24) antigen, predicts disease progression as well as CD4 lymphocyte count and HIV-1 RNA viral load, which are currently used to determine when patients should start antiviral drug therapy to prevent AIDS. The study, "Heat-Denatured Human Immunodeficiency Virus Type 1 Protein 24 Antigen: Prognostic Value in Adults with Early-Stage Disease," appears in the Oct. 15 issue of The Journal of Infectious Diseases.

Timothy R. Sterling, MD, a study co-author and assistant professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health said, "The test could be used to determine when to initiate antiretroviral therapy in HIV-infected persons. And because it costs much less than both CD4 lymphocyte count and HIV-1 RNA viral load, the heat-denatured p24 antigen test could be of particular benefit in developing countries, where the burden of HIV infection is great."

According to Dr. Sterling, CD4 lymphocytes and HIV-1 RNA are excellent predictors of disease progression and response to therapy and are used to determine when to initiate antiretroviral therapy. However, the current tests to monitor CD4 lymphocytes and HIV-1 RNA are expensive. The heat-denatured assay separates antigen-antibody complexes and increases the detection of p24 antigen in patients during the early-stages of the disease.

"P24 antigen is a protein in HIV. The test is administered by drawing blood from a patient, heating the plasma, and then measuring the amount of p24 antigen found in the sample. Higher levels of p24 indicates a greater risk of disease progression," explained Dr. Sterling. The authors found that a p24 level of 5 pg/ml was
'"/>

Contact: Kenna L. Brigham
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
16-Oct-2002


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader in ... Systems of Iowa as the Recycling Project of the ... the re-roofing of the SuperTarget retail store in Olathe, ... contractor and one of Target’s Preferred Tier One roofing ... building practices and they are a worthy recipient of ...
(Date:5/23/2013)... Professional Insurance Plans, an independent insurance ... celebrate Fibromyalgia Education and Awareness Month. As a ... country, the agency feels that it is important for ... that affects an estimated 10 million of Americans. , ... definition of Fibromyalgia (FM) is, “a common and complex ...
(Date:5/23/2013)... 23, 2013 Traditionally, laser skin therapy ... on skins of colour, this can be tricky. Based ... 1-1V may be treated safely with most lasers. Darker ... discoloration issues, have been left without recourse. Those who ... “clear” their skin successfully. , Hyperpigmentation occurs ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Statins are ... but the medications also could hamper heart patients, ability ... A small group of overweight or obese people ... taking a 40 milligram daily dose of simvastatin, while ... same exercise regimen did show improvement, found the study ...
(Date:5/23/2013)... PTSD , Soldiers returning home from combat may ... disorder if public support for a war effort is ... shapes the level of distress soldiers feel from the ... two experiments that asked participants to exterminate woodlice in ... actor show either interest or disgust for the act ...
Breaking Medicine News(10 mins):Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 3Health News:Statins May Hamper Workout Results 2Health News:Statins May Hamper Workout Results 3Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
Cached News: